Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Recruiting 5Terminated 3Completed 2Active not recruiting 2Not yet recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Prostatic Neoplasms 25Breast Neoplasms 19Multiple Myeloma 17Neoplasm Metastasis 15Lung Neoplasms 15Ovarian Neoplasms 14Lymphoma 14Glioma 14Carcinoma, Renal Cell 14Carcinoma, Non-Small-Cell Lung 12Pancreatic Neoplasms 11Fallopian Tube Neoplasms 11Melanoma 10Carcinoma, Hepatocellular 10Urinary Bladder Neoplasms 9Sarcoma 9Medulloblastoma 9Cholangiocarcinoma 9Neuroblastoma 8Glioblastoma 8Colonic Neoplasms 8Triple Negative Breast Neoplasms 7Thyroid Neoplasms 7Oropharyngeal Neoplasms 7Uterine Cervical Neoplasms 6Rhabdoid Tumor 6Rectal Neoplasms 6Neuroendocrine Tumors 6Mouth Neoplasms 6Lymphoma, Non-Hodgkin 6

Interventions

Rituximab 13Cyclophosphamide 10Lenalidomide 8venetoclax 5ibrutinib 5fludarabine 4CT-P10 4orelabrutinib 3obinutuzumab 3fludarabine phosphate 3Vincristine 3tafasitamab 2pirtobrutinib 2copanlisib 2acalabrutinib 2Whole-Body Irradiation 2Tacrolimus 2Specimen Handling 2Prednisone 2Nivolumab 2Mycophenolic Acid 2Melphalan 2Magnetic Resonance Spectroscopy 2Hyaluronoglucosaminidase 2Etoposide 2Doxorubicin 2Busulfan 2Bendamustine Hydrochloride 2selinexor 1prednylidene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Lymphoma, B-Cell, Marginal Zone × Magnetic Resonance Spectroscopy × Clear all
NCT01955499 2026-05-13

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

National Cancer Institute (NCI)

Phase 1 Active not recruiting
39 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04799275 2026-05-13

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
422 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡